Document:

EX-10.28(ii)

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and
filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

Exhibit 10.28(ii) 
  

			
		  	 

		
	Boehringer Ingelheim Pharma GmbH & Co. KG • 88397 Biberach an der Rise	  	
		
		  	 26 June 2008

	 FibroGen Inc.
 225 Gateway Boulevard

South San Francisco, CA 94080
 U. S. A.
	  	
	  
 Re: Postponement of exercise date for “BI Pharma Option Part
1” granted under the Process Development and Clinical Supply Agreement effective as of November 29, 2007 (the “Definitive Agreement”)
  

Dear Ladies and Gentlemen:
  

Under the Definitive Agreement FibroGen, Inc. (“FibroGen”) granted to Boehringer Ingelheim Pharma GmbH & Co. KG (“BI”, and
together with FibroGen, the “Parties”) a first option to manufacture and supply [ * ] Product (the “Option”), which must be exercised no later than [ * ].

 
 As described in the Definitive Agreement, the Parties have been engaged in negotiations
for a [ * ] supply agreement (the “Supply Agreement”) which, if BI exercises the Option, shall be finalized no later than [ * ].
  

As the negotiations require further discussion between the Parties, the purpose of this letter agreement (this “Letter Agreement”) is to set forth
the mutual agreement of FibroGen and BI with respect to an extension of the date by which the BI Pharma Option Part 1 as described in the Definitive Agreement must be exercised. Accordingly, FibroGen and BI agree that the Definitive Agreement shall
be amended as follows:
	  	

			
	  
 1. The second sentence of Section 6.1.1 of the Definitive Agreement
shall be amended to read as follows:
	  	
	  
 “Such option must be exercised by BI Pharma no later than [ *
], and such option will lapse if not exercised by BI Pharma by such date.”
	  	
	  
 2. The second sentence of Section 6.2 shall be deleted.
	  	
	  
 Except as expressly set forth in this Letter Agreement, all other terms
and conditions of the Definitive Agreement shall remain in full force and effect. This Letter Agreement may be executed in one or more counterparts, each of which shall constitute together the same document.
	  	
	  
 Please indicate your agreement with the matters set forth herein by
executing this Letter Agreement in the space provided below.
	  	
	  
 Very truly yours,
	  	

							
	  
 Boehringer Ingelheim Pharma

            ppa.
	 	  
 GmbH & Co. KG

     i. V.
	  	
	  
 By:
     [ * ]                                
                                   
	 		  	  

[ * ]                      
                                         
              
	  	
	Name: [ * ]	 		  	[ * ]	  	
	Title:   VP Supply Chain	 		  	Corporate Lawyer	  	

 Acknowledged and Agreed: 

FibroGen, Inc. 
  

			
	 By:
	 	 /s/ Thomas B. Neff

	 Name:
	 	Thomas B. Neff
	 Title:
	 	Chairman & CEO

  
 [ * ] = Certain confidential information contained in
this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.EX-10.28(iii)

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and
filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

Exhibit 10.28(iii) 
  

			
		  	 

  

	 FibroGen Inc.

225 Gateway Boulevard

South San Francisco, CA 94080

U. S. A.
	  
		  	 18 August 2008
  

	  
 Re: Postponement of exercise date for “BI Pharma Option Part
1” granted under, and final execution date of the “[ * ] supply agreement” according to the Process Development and Clinical Supply Agreement effective as of November 29, 2007 and amended by the Letter Agreement (the
“Letter Agreement”) effective as of June 26, 2008 (together the “Definitive Agreement”).
  

Dear Ladies and Gentlemen:
  

Under the Definitive Agreement FibroGen, Inc. (“FibroGen”) granted to Boehringer Ingelheim Pharma GmbH & Co. KG (“BI”, and
together with FibroGen, the “Parties”) a first option to manufacture and supply [ * ] Product (the “Option”), which must be exercised no later than [ * ].

 
 The Parties now agree, that the exercise of the Option and the negotiation of the
[ * ] supply agreement (the “Supply Agreement”) needs further postponement. As the Parties are engaged in negotiations for an Addendum No. 1 to the Definitive Agreement reflecting the changes discussed during the
previous months, the purpose of this second letter agreement (this “Letter Agreement No. 2”) is to set forth the mutual agreement of FibroGen and BI with respect to an extension of the date by which the Option as described in the
Definitive Agreement must be exercised and the Supply Agreement shall be finally executed. Accordingly, FibroGen and BI agree that the Definitive Agreement shall be amended as follows:

 
 1.         The second sentence of
Section 6.1.1 of the Definitive Agreement shall be amended to
             read as
follows:
  

            “Such option must be exercised by BI Pharma no later than [ * ],
and such option will
             lapse if not exercised by BI Pharma by such
date.”
	  	

			
	 Page 2 of 2
	  	

			
	  
 2.        The second sentence
(which has been the third sentence prior to deletion of the former
            second sentence by the
Letter Agreement) of Section 6.2 shall be amended to read as
            follows:

 
            “However, the final
execution date of said [ * ] supply agreement shall not be later than 

           [ * ].”

 
 Except as expressly set forth in this Letter Agreement No. 2, all other terms and
conditions of the Definitive Agreement shall remain in full force and effect. This Letter Agreement No. 2 may be executed in one or more counterparts, each of which shall constitute together the same document.

 
 Please indicate your agreement with the matters set forth herein by executing this Letter
Agreement No. 2 in the space provided below.
  
 Very truly yours,
	  	

													
	  
 Boehringer Ingelheim Pharma GmbH & Co.
KG
	 		  	
		 	             ppa.
	 		 	 i. V.
	 		 		  	
	  
 By:
	 	  
 [ * ]
	 		 	  

[ * ]
	 		  	
	 Name:
	 	 [ * ]
	 		 	 [ * ]
	 		  	
	 Title:
	 	 VP Supply Chain
	 		 	 Corporate Lawyer
	 		  	

 Acknowledged and Agreed: 

FibroGen, Inc. 
  

			
	 By:
	 	 /s/ William Hodder

			
	 Name:
	 	William Hodder
	 Title:
	 	Vice President, Business Development

  
 [ * ] = Certain confidential information
contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.EX-10.28(iv)

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been
omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

Exhibit 10.28(iv) 

Amendment No. 1 

(hereinafter called the “Amendment”) 

to the 
 Process Development
and Clinical Supply Agreement 
 effective as of 29 November 2007 and signed by the Parties 

on November 29 and December 03, 2007 

between 
 FibroGen Inc.

 409 Illinois St 
 San
Francisco, CA 94158 
 USA 

(hereinafter called “FibroGen”) 

and 
 Boehringer
Ingelheim Pharma GmbH & Co. KG 
 Birkendorfer Straße 65 

88397 Biberach an der Riß 

Germany 
 (hereinafter called
“BI Pharma”) 
 (each party individually called a “Party” and both parties collectively called the 

“Parties”). 
 Preamble 

The Parties entered into the Process Development and Clinical Supply Agreement, effective as of 29 November 2007 and signed by the Parties on
November 29 and December 03, 2007, which has been modified by the Letter Agreements entered into on 26 June 2008 and 18 August 2008 (hereinafter together called the “Agreement”). 

  
 1. 

 Amendment 1 to the Process Development and Clinical Supply Agreement between FibroGen / BI Pharma 

The Parties have agreed to update Appendix 2 of the Agreement due to their needs and hereby agree to modify the Agreement as follows: 

 

	1.	The current Appendix 2 of the Agreement “Project Plan including Project Timeline and Payment Schedule” shall be replaced by the “Master plan: Anti — CTGF FibroGen Inc. / BI Pharma GmbH & Co.
KG” (version of May 12, 2009), attached to this Amendment as Attachment 1. Any reference in the Agreement to the Appendix 2 shall be read to reference the new Appendix 2 as attached to this Amendment (including but not limited to the List
of Appendices on page 29 of the Agreement). 

  

	2.	This Amendment shall take effect as of the date of last signature below and as far as not amended herein, the Agreement shall remain in full force and effect. 

 

			
	Biberach, May 14, 2009	  	San Francisco, May 28, 2009
	  
 Boehringer Ingelheim

Pharma GmbH & Co. KG
	  	  
 FibroGen
Inc.

  

					
	ppa.	 	ppa.	  	
	  
 [ * ]
	 	  
 [ * ]
	  	  
 /s/ James Polarek

	[ * ]	 	[ * ]	  	James Polarek
		 		  	VP, Protein Therapeutics and Collagen Development

 Attachment 1:     Master plan: Anti- CTGF Fibrogen Inc./ BI Pharma GmbH & Co. KG (Version
of May 12, 2009) 
  
 [ * ] = Certain confidential information
contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 Amendment 1 to the Process Development and Clinical Supply Agreement between FibroGen / BI Pharma 

Attachment 1 
 [ * ] 

 
 [ * ] = Certain confidential information contained in this document, marked
by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.EX-10.28(v)

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and
filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

Exhibit 10.28(v) 

AMENDMENT NO. 3 TO PROCESS DEVELOPMENT AND
CLINICAL SUPPLY AGREEMENT 
 THIS AMENDMENT
NO. 3 (the “Third Amendment”) is effective retroactively as of November 5, 2010 (the “Third Amendment Effective Date”) by and between Boehringer Ingelheim Pharma GmbH & Co. KG,
Birkendorfer Straße 65, 88397 Biberach an der Riss, Germany (“BI Pharma”) and FibroGen, Inc., 409 Illinois Street, San Francisco, CA 94158, USA (“FibroGen”) amends the Process Development and Clinical Supply
Agreement entered into by and between BI Pharma and FibroGen on November 29, 2007, as amended pursuant to the letter agreements entered into as of June 26, 2008 and August 18, 2008, and the Amendment No. 1, effeactive as of
May 28, 2009 (hereinafter together the “Supply Agreement”). BI Pharma and FibroGen shall be referred to individually herein as a “Party”, and collectively as, the “Parties”. The Supply Agreement and this Third
Amendment are collectively, the “Agreement”. 
 WHEREAS, FibroGen wishes to engage BI Pharma to conduct
additional [ * ], in compliance with the terms of the Supply Agreement. 
 NOW,
THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties agree as follows: 
  

	 	(1)	Unless otherwise defined herein, all capitalized terms and phrases used in this Third Amendment shall have the meaning ascribed to them in the Supply Agreement. 

 

	 	(2)	The Parties hereby agree that the [ * ] that shall be performed by BI Pharma shall be considered part of the Project and therefore, pursuant to Section 2.2 of the Agreement, the Exhibit “Work
Scope and Cost Estimate for [ * ]”, attached to this Third Amendment shall be added as an amendment to the existing Appendix 2 of the Agreement, and pursuant thereto BI Pharma shall conduct a [ * ] on behalf of
FibroGen, and in accordance with the Supply Agreement. 

  

	 	(3)	This Third Amendment, together with the Agreement, contains the entire understanding of the Parties with respect to the subject matter hereof. Except as otherwise provided herein, the Agreement has not been modified or
amended and remains in full force and effect. All express or implied agreements and understandings that conflict with the terms of this Third Amendment, either oral or written, heretofore made with respect to subject matter herein are expressly
superseded by this Third Amendment. 

  

	 	(4)	This Third Amendment may be executed in counterparts, each of which shall be deemed an original, and all of which together shall constitute one and the same instrument. Counterparts may be signed and delivered by
facsimile and/or via portable document format (pdf) (or similar format), each of which shall be binding when sent. 

  

					
	 CONFIDENTIAL
	  	1	  	

 IN WITNESS WHEREOF, the Parties have executed this Third Amendment to the Agreement as of Third
Amendment Effective Date. 
  

			
	FIBROGEN, INC.
		
	By:	 	 /s/ Jim Polarek

			
	Name:	 	 Jim Polarek

			
	Title:	 	 VP, Protein Therapeutics and Collagen
Development

			
	Date:	 	     December 13, 2010

  

			
	BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG
	 ppa.

		
	By:	 	 [ * ]

			
	Name:	 	[ * ]
	Title:	 	Head of ICB, SCM

  

			
	BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG
	 i. V.

		
	By:	 	 [ * ]

			
	Name:	 	[ * ]
	Title:	 	Lawyer
	Date:	 	November 22, 2010

 Exhibit: Work Scope and Cost Estimate for [ * ] (Version 3, 2010) 

  

					
	CONFIDENTIAL	 	2	 	

  
 [ * ] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00236-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00236-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00236-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00236-of-00352.parquet"}]]